JENNIFER RUSSO: Open Payments
NPI 1407200413 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,956 in 115 payments from 15 companies in 2025. Trend: 2023 $631 · 2024 $2,028 · 2025 $2,956
Food & beverage: $2,956
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 43 | $814 |
| ABBVIE INC. | 27 | $659 |
| Otsuka America Pharmaceutical, Inc. | 16 | $374 |
| E.R. Squibb & Sons, L.L.C. | 5 | $183 |
| Collegium Pharmaceutical, Inc. | 5 | $166 |
| Alkermes, Inc. | 4 | $157 |
| Axsome Therapeutics, Inc. | 2 | $149 |
| Vanda Pharmaceuticals Inc. | 1 | $122 |
| Tris Pharma Inc | 5 | $116 |
| Janssen Pharmaceuticals, Inc | 1 | $95 |
Products named: CAPLYTA, VRAYLAR, COBENFY, Jornay PM, ARISTADA, REXULTI, Auvelity, FANAPT.
Industry payments across NV — which companies pay providers there.
